Thomas J. Schwan

543 total citations
54 papers, 355 citations indexed

About

Thomas J. Schwan is a scholar working on Organic Chemistry, Molecular Biology and Cancer Research. According to data from OpenAlex, Thomas J. Schwan has authored 54 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Organic Chemistry, 13 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Thomas J. Schwan's work include Synthesis and Characterization of Heterocyclic Compounds (8 papers), Synthesis and Biological Activity (8 papers) and Synthesis of heterocyclic compounds (7 papers). Thomas J. Schwan is often cited by papers focused on Synthesis and Characterization of Heterocyclic Compounds (8 papers), Synthesis and Biological Activity (8 papers) and Synthesis of heterocyclic compounds (7 papers). Thomas J. Schwan collaborates with scholars based in United States, Germany and South Africa. Thomas J. Schwan's co-authors include B. R. Baker, S.F. Pong, Howard Tieckelmann, Peter Sander, Daniel V. Santi, Robert L. White, K.O. Ellis, Khean‐Lee Goh, Robert Benamouzig and Jaroslav Novotný and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and Journal of Pharmaceutical Sciences.

In The Last Decade

Thomas J. Schwan

47 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas J. Schwan United States 11 192 92 83 81 21 54 355
Teruki Hamada Japan 9 97 0.5× 126 1.4× 55 0.7× 76 0.9× 20 1.0× 18 318
Richard L. Wolgemuth United States 8 55 0.3× 97 1.1× 15 0.2× 66 0.8× 105 5.0× 17 308
Mitsuhiro Kinoshita Japan 10 181 0.9× 105 1.1× 9 0.1× 32 0.4× 35 1.7× 25 328
Clara I. Villamil United States 11 194 1.0× 143 1.6× 14 0.2× 12 0.1× 78 3.7× 16 369
H. Glasner Germany 10 77 0.4× 73 0.8× 62 0.7× 69 0.9× 136 6.5× 25 375
Filippo Ingoglia Italy 8 50 0.3× 71 0.8× 27 0.3× 26 0.3× 90 4.3× 11 245
Chie Nakagawa Japan 8 138 0.7× 46 0.5× 20 0.2× 34 0.4× 18 0.9× 12 326
Wonkyo Shin South Korea 10 138 0.7× 59 0.6× 12 0.1× 17 0.2× 33 1.6× 40 325
Ruijuan Luo United States 10 95 0.5× 194 2.1× 11 0.1× 13 0.2× 90 4.3× 15 431
Eman A. Ahmed Egypt 10 228 1.2× 37 0.4× 11 0.1× 59 0.7× 51 2.4× 34 385

Countries citing papers authored by Thomas J. Schwan

Since Specialization
Citations

This map shows the geographic impact of Thomas J. Schwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Schwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Schwan more than expected).

Fields of papers citing papers by Thomas J. Schwan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Schwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Schwan. The network helps show where Thomas J. Schwan may publish in the future.

Co-authorship network of co-authors of Thomas J. Schwan

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Schwan. A scholar is included among the top collaborators of Thomas J. Schwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Schwan. Thomas J. Schwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mönnikes, Hubert, Thomas J. Schwan, Christo Van Rensburg, et al.. (2013). Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial. BMC Gastroenterology. 13(1). 145–145. 6 indexed citations
2.
3.
Rensburg, Christo Van, et al.. (2008). Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Current Medical Research and Opinion. 24(7). 2009–2018. 25 indexed citations
4.
Goh, Khean‐Lee, Robert Benamouzig, Peter Sander, & Thomas J. Schwan. (2007). Efficacy of pantoprazole 20???mg daily compared with esomeprazole 20???mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial ??? the EMANCIPATE study. European Journal of Gastroenterology & Hepatology. 19(3). 205–211. 26 indexed citations
5.
Meusburger, Peter & Thomas J. Schwan. (2003). Humanökologie : Ansätze zur Überwindung der Natur-Kultur-Dichotomie. F. Steiner eBooks. 2 indexed citations
6.
Schwan, Thomas J., et al.. (1991). Depression of NMDA-Evoked Acetylcholine Release by Endogenous Adenosine in Striatum Slices. Advances in experimental medicine and biology. 287. 241–248. 2 indexed citations
7.
White, Robert L., et al.. (1987). 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones, a new class of skeletal muscle relaxants. Journal of Medicinal Chemistry. 30(2). 263–266. 17 indexed citations
8.
Becker, Ann, et al.. (1981). [Neutralizing capacity, pepsin inactivation and binding to bile acids and lysolecithin of the antacid magaldrate (author's transl)].. PubMed. 31(3). 504–7. 2 indexed citations
9.
Schwan, Thomas J., et al.. (1980). Synthesis and Antidepressant Activity of 5- (4-Dimethylaminobenzyl)imidazolidine-2,4-dione. Journal of Pharmaceutical Sciences. 69(9). 1102–1104. 45 indexed citations
10.
Schwan, Thomas J., et al.. (1979). 4-acetoxy-1,2,3,4-tetrahydro-2,2-dimethyl-6,7-methylenedioxyisoquinolinium Iodide, an Acetylcholine Analog. Journal of Pharmaceutical Sciences. 68(10). 1325–1326.
11.
Schwan, Thomas J., et al.. (1978). Anti-Inflammatory 1-Substituted 2-Imidazolidinones. Journal of Pharmaceutical Sciences. 67(4). 548–549.
12.
Schwan, Thomas J., et al.. (1978). Synthesis of an Anti-Inflammatory 10,10a-Dihydro-lH,5H-imidazo[l,5-b]isoquinoline-l,3(2H)-dione. Journal of Pharmaceutical Sciences. 67(5). 718–719. 3 indexed citations
13.
Ellis, K.O., et al.. (1978). Synthesis and comparative skeletal muscle relaxant activity of some 2,4-imidazolidinediones and their corresponding 5-hydroxy-2,4-imidazolidinediones. Journal of Medicinal Chemistry. 21(1). 127–130. 1 indexed citations
14.
Schwan, Thomas J., et al.. (1976). β‐(5‐Pyrimidinyl)ethanolamines. Journal of Heterocyclic Chemistry. 13(5). 973–976. 3 indexed citations
15.
Schwan, Thomas J., et al.. (1974). Synthesis and structural assignment of 5,6‐dihydro‐8‐hydroxy‐9‐methoxy‐1H,7H‐benzo[ij] quinolizine‐1,7‐dione. Journal of Heterocyclic Chemistry. 11(6). 849–851. 1 indexed citations
16.
Schwan, Thomas J., et al.. (1972). New Compounds: Resolution of d,l-α-Benzamido-4-hydroxy-3-methoxydihydrocinnamic Acid, a Precursor of l-3,4-Dihydroxyphenylalanine. Journal of Pharmaceutical Sciences. 61(9). 1506–1507.
17.
Baker, B. R., et al.. (1967). Irreversible Enzyme Inhibitors LXXII. Journal of Pharmaceutical Sciences. 56(1). 38–42. 5 indexed citations
18.
Baker, B. R., Thomas J. Schwan, & Daniel V. Santi. (1966). Nonclassical Antimetabolites. XXV.1 Inhibitors of Thymidine Kinase. I. A New Spectrophotometric Assay. Inhibition by Nucleoside Derivatives. Journal of Medicinal Chemistry. 9(1). 66–72. 20 indexed citations
19.
Schwan, Thomas J. & Howard Tieckelmann. (1965). The synthesis and some reactions of 2‐methyl‐4,5‐pyrimidinediearbonitrile. Journal of Heterocyclic Chemistry. 2(2). 202–205. 4 indexed citations
20.
Schwan, Thomas J. & Howard Tieckelmann. (1964). The halogen‐nitrile exchange reaction as a route to pyrimidinecarbonitriles. Journal of Heterocyclic Chemistry. 1(4). 201–202. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teruki Hamada Breakdown of academic impact, for papers by Richard L. Wolgemuth Breakdown of academic impact, for papers by Mitsuhiro Kinoshita Breakdown of academic impact, for papers by Clara I. Villamil Breakdown of academic impact, for papers by H. Glasner Breakdown of academic impact, for papers by Filippo Ingoglia Breakdown of academic impact, for papers by Chie Nakagawa Breakdown of academic impact, for papers by Wonkyo Shin Breakdown of academic impact, for papers by Ruijuan Luo Breakdown of academic impact, for papers by Eman A. Ahmed
Rankless by CCL
2026